Overlake Hospital Medical Center

Below are some of the SCCA clinical trials now being offered for patients at Overlake Hospital Medical Center. If you have any questions about these or other trials, please contact Cancer Center at Overlake.

Breast Cancer (Newly Diagnosed)

• Whole vs Partial Breast Irradiation for Stage 0, I, or II Breast Cancer (NSABP B-39)
  A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women With Stage 0, I, or II Breast Cancer
• Chemo w/wo Traztuzumab After Surgery for Invasive Breast Cancer (NSABP B-47)
  A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab (Herceptin) in Women with Node-Positive or High-Risk Node-Negative HER@-Low Invasive Breast Cancer

Breast Cancer (Recurrent/Metastatic)

• Triple Negative (6628)
  Combined Targeted Therapies for Triple Negative Advanced Breast Cancer - A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib
• WBI Versus PBI for Women with Stage 0, I or II Breast Cancer (NSABP B-39)
  A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I or II Breast Cancer
• Herceptin + Radiation Therapy for HER2-Positive Resected by Lumpectomy (NSABP B-43)
  A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

Colon Cancer (Newly Diagnosed/Recurrent)

• Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery (NSABP P-5)
  Statin Polyp Prevention Trial in Patients with Resected Colon Cancer

Leukemia (Newly Diagnosed)

• Vorinostat + Chemotherapy for CLL or SLL (PSOC-2401)
  A Phase I/II Study of Fludarabine (F), Cyclophosphamide ©), Rituximab ®), and Vorinostat (V) Followed by RV Maintenance Therapy in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small LymphoCtic Lymphoma (SLL)

Leukemia (Recurrent/Metastatic)

• Bexxar Consolidation CLL or SLL (PSOC 2301)
  A Study of 131-Tositumomab (Bexxar) Consolidation In Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma In First Remission

Lymphoma (Newly Diagnosed)

• Vorinostat + Chemotherapy for CLL or SLL (PSOC-2401)
  A Phase I/II Study of Fludarabine (F), Cyclophosphamide ©), Rituximab ®), and Vorinostat (V) Followed by RV Maintenance Therapy in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small LymphoCtic Lymphoma (SLL)

Lymphoma (Recurrent/Metastatic)

• Bexxar Consolidation CLL or SLL (PSOC 2301)
  A Study of 131-Tositumomab (Bexxar) Consolidation In Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma In First Remission
• TREC for Relapsed or Refractory Lymphoid Malignancies (PSOC 2502)
  A Phase I Trial of Bendamustine/Treanda, Rituxmab, Etoposide, and Carboplatin (TREC) for Patients With Relapsed or Refractory Lymphoid Malignancies